Oura S, Sakurai T, Yoshimura G, Tamaki T, Umemura T, Kokawa Y, Naito Y, Suzuma T, Tanino H
Dept. of Surgery, Wakayama Medical College Kihoku Hospital.
Gan To Kagaku Ryoho. 1999 May;26(6):781-8.
To evaluate the efficacy of docetaxel therapy against anthracycline-resistant breast cancer, twenty patients were treated with docetaxel. Of the 20 patients pretreated with anthracycline, 17 were clinically anthracycline-resistant and the remaining three were refractory to anthracycline on histoculture drug response assay. Nine patients had loco-regional recurrence and 11 had distant +/- loco-regional recurrence. Docetaxel (49-60 mg/m2) was administered every 4 weeks, and was infused 1-13 times (median; 3 times). Of the 19 evaluable patients, eight (42%) showed partial response with the docetaxel therapy. Durations of the response ranged from 1 to 8 months (median; 4 months). Major adverse effects of the therapy were alopecia, neutropenia, and leucocytopenia. Hypersensitivity reaction was observed in one case. In addition, severe adverse effects such as grade 2 pneumonia and grade 4 diarrhea were found in one patient each. In conclusion, although the adverse effects are not negligible, docetaxel therapy is effective against anthracycline-resistant breast cancer.
为评估多西他赛治疗蒽环类耐药乳腺癌的疗效，对20例患者采用多西他赛进行治疗。在这20例接受过蒽环类药物预处理的患者中，17例临床上对蒽环类药物耐药，其余3例在组织培养药物反应试验中对蒽环类药物难治。9例患者有局部区域复发，11例有远处转移伴或不伴局部区域复发。多西他赛（49 - 60 mg/m²）每4周给药一次，输注1 - 13次（中位数；3次）。在19例可评估的患者中，8例（42%）接受多西他赛治疗后出现部分缓解。缓解持续时间为1至8个月（中位数；4个月）。该治疗的主要不良反应为脱发、中性粒细胞减少和白细胞减少。1例患者出现过敏反应。此外，分别有1例患者出现2级肺炎和4级腹泻等严重不良反应。总之，尽管不良反应不容忽视，但多西他赛治疗蒽环类耐药乳腺癌是有效的。
